LANREOTIDE
LANREOTIDE
| SMILES | CC(C)[C@@H]1NC(=O)[C@H](CCCCN)NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@@H](NC(=O)[C@H](N)Cc2ccc3ccccc3c2)CSSC[C@@H](C(=O)N[C@H](C(N)=O)[C@@H](C)O)NC1=O |
| InChIKey | PUDHBTGHUJUUFI-SCTWWAJVSA-N |
Chemical Properties
| Hydrogen bond acceptors | None |
| Hydrogen bond donors | None |
| Rotatable bonds | None |
| Molecular weight (Da) |
Database connections
No bioactivity data available.
LANREOTIDE
Drug properties
| Molecular type | Protein |
| Physiological/Surrogate | Surrogate |
| Approved drug | Yes |
Clinical Trials
Phase I
0
Phase II
12
Phase III
12
Approved
Yes
Database connections
Sankey plot
, 'sankey.svg');){kind=link}
, 'sankey.png');){kind=link}
,'sankey.jpg');){kind=link}
Drug Information
| Target | Disease | Phase | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Gene | Protein | Receptor family | Ligand type | Class | Indication name | ICD11 | ATC | Association score | Phase | Approved |